Nurix reports
Nurix reports promising preclinical data for IRAK4 degrader GS-6791
SAN FRANCISCO - Nurix Therapeutics, Inc. announced preclinical data for GS-6791, a novel IRAK4 protein degrader developed under its research collaboration with Gilead Sciences. The findings, presented Wednesday at the European Academy of Dermatology and Venereology Congress in Paris, support the compound’s advancement into clinical testing. According to InvestingPro data, Nurix maintains a strong liquidity position with a current ratio of 6.82, though the company is experiencing rapid cash burn as it advances its pipeline.
The data show GS-6791 achieves sustained degradation of IRAK4, a signaling protein involved in toll-like receptor and interleukin-1 family receptor pathways. In preclinical studies, the oral compound demonstrated robust inhibition of IL-1 and IL-36-driven responses in skin epithelial cell systems and reduced disease severity in an atopic dermatitis model.
According to the company, GS-6791 achieved near-complete IRAK4 knockdown in human blood and keratinocytes while reducing proinflammatory cytokines and disease-associated gene expression in skin models.
Gilead exercised its option to license GS-6791 in March 2023 and received FDA clearance for its Investigational New Drug application in April 2025. A Phase 1 trial evaluating safety, tolerability, and pharmacodynamics in healthy volunteers is currently underway.
"These findings underscore the opportunity for targeted protein degradation to address complex immune signaling pathways and expand treatment possibilities for patients with inflammatory diseases," said Gwenn Hansen, chief scientific officer at Nurix, in the press release.
Under the 2019 collaboration agreement, Nurix has received $135 million to date and remains eligible for up to $420 million in potential milestone payments for the IRAK4 program, plus royalties on net sales. Nurix retains options to co-develop and co-detail up to two programs in the United States.
The collaboration has produced multiple drug candidates, including a preclinical STAT6 degrader and the clinical-stage IRAK4 degrader GS-6791.
In other recent news, Nurix Therapeutics has been the focus of several analyst updates following its second-quarter financial results. Morgan Stanley adjusted its price target for Nurix to $16, citing higher anticipated spending for planned pivotal trials. UBS also lowered its price target to $26, attributing the change to increased operational expenses. Meanwhile, Stifel maintained its Buy rating and $35 price target, projecting potential peak sales of over $4.5 billion for Nurix’s lead drug candidate. Goldman Sachs initiated coverage with a Buy rating and set a notably higher price target of $182, expecting the launch of Nurix’s Crenessity drug to mitigate potential challenges to Ingrezza growth. These updates reflect varying perspectives on Nurix’s financial outlook and strategic developments. Stifel anticipates Nurix will announce development plans for its lead drug candidate in the latter half of 2025. The focus on financial adjustments and drug development plans highlights the dynamic environment surrounding Nurix.
